대한임상미생물학회


EUCAST news update (2024.06.30)

  • 작성자

    홍성근
  • 작성일자

    2024-07-02 16:50
  • 조회수

    40

 

EUCAST Logo  

EUCAST news and updates

Dear colleagues,

The following news items have been published in the previous month:

  • 30 Jun 2024:  Updated expert rules

    Expert rules updated for Enterobacterales and Enterococcus. 

     

  • 25 Jun 2024:  Bacillus anthracis breakpoints published in CMI

    European multi-centre study to establish MIC and zone diameter epidemiological cut-off values for Bacillus anthracis

     

    Flavia Dematheis, Viviana Manzulli, Gregor Grass, Erika Matuschek, Daniela Jacob, Falk Melzer, Mandy Elschner, Agnieszka Kedrak-Jablonska, Sylwia Budniak, Marcella Mori, Tiziano Fancello, Roland Grunow, Gunnar Kahlmeter, Domenico Galante, Sabine Zange. Clin Microbiol Infect 2024 Jun 7:S1198-743X(24)00256-8. DOI: 10.1016/j.cmi.2024.05.019

     

  • 23 Jun 2024:  The EUCAST subcommittee on phage susceptibility testing formed

    A webpage dedicated to the EUCAST ad hoc subcommittee on phage susceptibility testing is under construction.

     

     

     

  • 18 Jun 2024:  The EUCAST subcommittee on the role of WGS in AST re-established

    The EUCAST subcommittee on the role of whole genome sequencing in antimicrobial susceptibility testing has been re-established, under the leadership of Antonio Oliver (Spain).

     

    These are the findings and the conclusions of the previous subcommittee, published in 2017 (https://doi.org/10.1016/j.cmi.2016.11.012):

     

    Whole genome sequencing (WGS) offers the potential to predict antimicrobial susceptibility from a single assay. The European Committee on Antimicrobial Susceptibility Testing established a subcommittee to review the current development status of WGS for bacterial antimicrobial susceptibility testing (AST).

     

    The published evidence for using WGS as a tool to infer antimicrobial susceptibility accurately is currently either poor or non-existent and the evidence / knowledge base requires significant expansion. The primary comparators for assessing genotypic–phenotypic concordance from WGS data should be changed to epidemiological cut-off values in order to improve differentiation of wild-type from non-wild-type isolates (harbouring an acquired resistance). Clinical breakpoints should be a secondary comparator. This assessment will reveal whether genetic predictions could also be used to guide clinical decision making. Internationally agreed principles and quality control (QC) metrics will facilitate early harmonization of analytical approaches and interpretive criteria for WGS-based predictive AST. Only data sets that pass agreed QC metrics should be used in AST predictions. Minimum performance standards should exist and comparative accuracies across different WGS laboratories and processes should be measured. To facilitate comparisons, a single public database of all known resistance loci should be established, regularly updated and strictly curated using minimum standards for the inclusion of resistance loci. For most bacterial species the major limitations to widespread adoption for WGS-based AST in clinical laboratories remain the current high-cost and limited speed of inferring antimicrobial susceptibility from WGS data as well as the dependency on previous culture because analysis directly on specimens remains challenging.

     

    For most bacterial species there is currently insufficient evidence to support the use of WGS-inferred AST to guide clinical decision making. WGS-AST should be a funding priority if it is to become a rival to phenotypic AST. This report will be updated as the available evidence increases./ 2017

     


Please visit the EUCAST News page to read more.

All changes to the EUCAST website and to AST recommendations and guidance are listed in a table on the EUCAST website!

With kind regards,
EUCAST

 
 
  ESCMID Executive Office
Aeschenvorstadt 55
4051 Basel
Switzerland
Phone +41 61 508 0150
info@escmid.org
www.escmid.org
Follow ESCMID
Follow us on mastodon Visit us on LinkedIn Visit us on YouTube
The EUCAST Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of EUCAST-related matters and other information of interest to professionals in the infection field.